These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37938521)

  • 21. Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention.
    Caimi B; Franzetti M; Velleca R; Lai A; Gatti A; Rossi PL; D'Orso M; Pregliasco F; Balotta C; Calicchio G
    BMC Geriatr; 2022 Mar; 22(1):191. PubMed ID: 35272615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
    Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
    BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination.
    Eren-Kutsoylu OO; Appak O; Nazli-Zeka A; Omeroglu-Simsek G; Tekin N; Bayram B; Sayiner AA; Tanglay N; Avkan-Oguz V
    Ir J Med Sci; 2023 Feb; 192(1):263-268. PubMed ID: 35829907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities.
    Causa R; Almagro-Nievas D; Rivera-Izquierdo M; Benítez-Muñoz N; López-Hernández B; García-García F; Alvarez-Estévez M; Soto-Pérez MO; Bermúdez-Tamayo C
    Gerontology; 2022; 68(8):910-916. PubMed ID: 34758461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster.
    McConeghy KW; Bardenheier B; Huang AW; White EM; Feifer RA; Blackman C; Santostefano CM; Lee Y; DeVone F; Halladay CW; Rudolph JL; Zullo AR; Mor V; Gravenstein S
    JAMA Netw Open; 2022 Dec; 5(12):e2245417. PubMed ID: 36477482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.
    Goldin S; Adler L; Azuri J; Mendel L; Haviv S; Maimon N
    Gerontology; 2022; 68(12):1350-1357. PubMed ID: 35134810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
    Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
    Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
    Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
    Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults.
    Rastawicki W; Juszczyk G; Gierczyński R; Zasada AA
    J Clin Virol; 2022 Jul; 152():105193. PubMed ID: 35660747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities.
    Naschitz JE; Kertes J; Pinto G; Zaigraykin N; Oz D; Goland E; Nasser S; Supino-Rosin L; Lazar R; Ekka-Zohar A
    Infect Dis (Lond); 2022 Apr; 54(4):292-296. PubMed ID: 34918582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
    Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
    Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.